News

CMND-100 is Clearmind’s proprietary MEAI-based oral drug candidate, developed as a potential breakthrough treatment for AUD. Unlike traditional treatment methods, CMND-100 is designed to offer a novel ...
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development ...
This marks a key milestone as the Company prepares to initiate its FDA-approved Phase I/IIa clinical ... are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange ...
This marks a key milestone as the Company prepares to initiate its FDA-approved Phase I/IIa clinical trial for the ... Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and ...
Detailed price information for Spectral Medical Inc (EDT-T) from The Globe and Mail including charting and trades.
This study is the first clinical application of the Company’s proprietary CMND-100 platform and marks a significant milestone in the Company ... is a significant step in our journey toward FDA ...
The company announced that its oral investigational drug, neflamapimod, was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA ... of this milestone, noting that ...